Papamichael, K., Chachu, K. A., Vajravelu, R. K., Vaughn, B. P., Ni, J., Osterman, M. T., & Cheifetz, A. S. (2017). Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab. Clinical gastroenterology and hepatology, 15(10), 1580. https://doi.org/10.1016/j.cgh.2017.03.031
Citácia podle Chicago (17th ed.)Papamichael, Konstantinos, Karen A. Chachu, Ravy K. Vajravelu, Byron P. Vaughn, Josephine Ni, Mark T. Osterman, a Adam S. Cheifetz. "Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab." Clinical Gastroenterology and Hepatology 15, no. 10 (2017): 1580. https://doi.org/10.1016/j.cgh.2017.03.031.
Citácia podľa MLA (8th ed.)Papamichael, Konstantinos, et al. "Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab." Clinical Gastroenterology and Hepatology, vol. 15, no. 10, 2017, p. 1580, https://doi.org/10.1016/j.cgh.2017.03.031.